Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Want To Add A Drug Coating To Your Device? Check FDA's New Guide

Executive Summary

A new US FDA draft guidance on combination products is mostly a high-level view of agency regulatory pathways, but the document's annex digs a little deeper on considerations specifically for drug-coated devices.

You may also be interested in...



Guidance To Put More Combo Products Into Device Realm Due Out In Fall, FDA Commish Gottlieb Tells Congress

A combination products guidance “to move more products into the device realm” will be released either at the end of this summer or in early fall, US FDA Commissioner Scott Gottlieb told lawmakers at a hearing. He also explained how new 21st Century Cures authority to hire biomedical scientists with very specific expertise will help the agency.

FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks

The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.

Device Week, March 8, 2019 – Scott Gottlieb Resigns

On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel